Phase 3 Primary Biliary Cholangitis Trial, Recruiting NCT07296458 Sponsor: Xijing Hospital of Digestive Diseases Condition: Primary Biliary Cholangitis
Back to Primary Biliary Cholangitis

Phase 3 Primary Biliary Cholangitis Trial, Recruiting

NCT07296458
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part voluntarily and are able to understand and sign a consent form
  • You are aged 18 or older but under 75 years old
  • You have been diagnosed with primary biliary cholangitis (PBC) based on recognised medical guidelines, confirmed by at least two of these three things: certain positive blood markers (AMA, gp210, or sp100), an elevated liver enzyme called ALP, or specific findings on a liver tissue sample (confirm with trial site)
  • You have not taken UDCA or fenofibrate (specific liver/cholesterol medicines) in the 6 months before joining, and your ALP blood level is above the normal range

Who may not be able to join:

  • You have another liver condition at the same time, such as viral hepatitis, alcoholic liver disease, fatty liver disease, drug-related liver damage, autoimmune hepatitis, or primary sclerosing cholangitis
  • You are pregnant, breastfeeding, or planning to become pregnant during the study
  • You have a known allergy to fenofibrate or ursodeoxycholic acid (UDCA)
  • You have ever had, or currently have, serious liver complications such as bleeding from swollen veins, confusion caused by liver failure, fluid build-up in the abdomen, liver cancer, or liver-kidney syndrome
  • You have a history of serious problems with your heart, brain, kidneys, or lungs, or have a significant mental health condition (including those linked to alcohol or drug use)
  • Your liver enzyme or bilirubin (a measure of liver function) levels are significantly above the normal range (confirm with trial site)
  • Your kidney function blood test results are above or below certain thresholds (confirm with trial site)
  • You have taken certain other specific liver or cholesterol medications (such as obeticholic acid or other fibrate-type drugs) within the past 6 weeks
  • You have taken certain other medicines including colchicine, methotrexate, or azathioprine, or have had steroid treatment, for more than 2 weeks in the past 2 months
  • You are currently taking immune-suppressing medications such as cyclosporine or tacrolimus
  • You are planning to have, or have already had, an organ transplant
  • You have HIV or tested positive for HIV during screening
  • You have been diagnosed with or treated for cancer in the past 2 years
  • The trial team considers there to be another reason you would not be suitable to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Xijing Hospital of Digestive Diseases
Registry
ClinicalTrials.gov
Start date
15 December 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Percentage of Participants with Normal ALP level

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov